ABOUT SK PHARMTECO
At SK pharmteco our mission is to build strong relationships that create happiness for our customers through the shared goal of producing and delivering life-changing therapies that improve patient outcomes and save lives. With our network of seven global, cutting-edge, facilities our capabilities cover the entire product lifecycle, from initial development to commercial manufacturing. We work with customers in a flexible ‘One Team’ approach, prioritizing collaboration, transparency, and trust to make every interaction easy and seamless.
SK pharmteco offers CDMO services for small molecule, Gene therapy, and Analytical testing, contact our experts to learn more!
CONTACT INFORMATION
SK pharmteco
12460 Akron St #100
Rancho Cordova, CA 95742
Contact: Liza Rivera
SMALL MOLECULE
-
SK Pharmteco Capabilities Update October 2026: Small Molecule Drug Substance
Backed by decades of experience and a proven track record of quality, this organization deliver programs from early-phase to commercial manufacturing.
-
Solvent Recovery Systems For Sustainable Pharma Manufacturing
Solvent recovery can reduce waste, but scaling it brings technical and regulatory risks. See how three approaches performed and what it takes to move from bench to commercial scale.
-
Crude Peptide Purification Optimization For Scalable Manufacturing
Transitioning lentiviral vectors to final drug product raises quality demands. A simplified membrane-based capture step minimizes downstream losses that can constrain systemic dosing.
-
GLP-1 Peptides Around The World Part III: EU Evolution – Expanded Expectations And Emerging Enforcement
Navigating GLP-1 development in Europe? Discover how stricter CMC, Annex 1, serialization, and supply chain requirements are influencing manufacturing strategies.
-
Making Complex Science Dependable
Advance small molecule programs with the right mix of scientific expertise, scalable manufacturing, regulatory readiness, and analytical support from discovery to launch.
-
GLP-1 Peptides Around The World
Explore how evolving regulations, supply constraints, and reimbursement models shape GLP-1 drug development across the U.S., Europe, and Asia.
-
Addressing The Acetonitrile Supply By Implementing Strategies
Rising acetonitrile demand threatens supply chains; recovery and reuse methods using evaporation and crystallization produce high‑purity solvent, reducing costs, waste, and reliance on fresh supply.
-
SK Pharmteco Capabilities Update March 2026: Small Molecule Drug Substance
Join Frank Mueller, Executive Director of Business Development, for an overview of our capabilities and global capacity spanning North America, Europe, and Asia.
-
Spray Drying Applications In The Pharmaceutical Industry
Spray drying turns liquids into uniform powders, improving stability, solubility, flowability, and bioavailability while allowing precise control of particle traits.
-
Chromatography That Conquers Complexity
Supported by specialized containment infrastructure and deep HPAPI expertise, our chromatography capabilities ensure safe handling of highly potent compounds while delivering consistent, high-quality purification outcomes.
CELL & GENE THERAPY
-
SKyvec™ Lenti For In Vivo Applications
When lentiviral vector moves from ex vivo intermediate to in vivo final drug product, purity, potency, and consistency expectations rise, and downstream capture performance becomes a central constraint.
-
Simplifying Adenoviral Purification For Scalable Manufacturing
As vector design advances, downstream purification limits adenoviral manufacturing. A membrane-integrated hybrid train reduces product loss and process complexity at scale.
-
Crude Peptide Purification Optimization For Scalable Manufacturing
Transitioning lentiviral vectors to final drug product raises quality demands. A simplified membrane-based capture step minimizes downstream losses that can constrain systemic dosing.
-
GLP-1 Peptides In Asia: Expanding Access And Opportunity
Asia's growing role in the GLP-1 market presents new opportunities and challenges. Learn how regulatory preparedness, scalable manufacturing, and robust quality systems can enable growth.
-
Viral Vector Services
Fast-track your Gene Therapies from cutting-edge process development to commercial success with advanced viral vector manufacturing solutions!
-
GLP-1 Peptides Around The World Part III: EU Evolution – Expanded Expectations And Emerging Enforcement
Navigating GLP-1 development in Europe? Discover how stricter CMC, Annex 1, serialization, and supply chain requirements are influencing manufacturing strategies.
-
SK Pharmteco Capabilities Update July 2026: Gene Therapy
Adaptive viral vector platforms pair scalable manufacturing with targeted purification. Customizing workflows ensures high vector purity and cost efficiency, accelerating clinical development.
-
Solving Challenges For Vectors That Are Complex In Practice
Overcome adenoviral scale-up challenges with a design-to-scale manufacturing framework that optimizes cell growth, boosts vector productivity, and supports reliable clinical supply.
-
Maximizing Efficiency In Lentiviral Vector Manufacturing
Accelerate cell and gene therapy programs with scalable lentiviral vector manufacturing, delivering high titers, exceptional purity, and reliable clinical supply from gene to clinic.
-
Optimizing Adenoviral Production With Adaptive Process Architecture
Speed adenoviral vector development with scalable suspension processes and hybrid purification workflows that improve yield, efficiency, and clinical readiness.
CONTRACTS & ANALYTICAL
-
History Of Peptides In Medicine: From Early Chemistry To The GLP-1 Era
Peptide therapeutics from early chemical breakthroughs to today’s metabolic drugs, highlighting scientific, clinical, and manufacturing advances shaping modern drug development.
-
The Evolving Landscape Of HPAPI Contract Manufacturing
Surging demand for highly potent drugs is driven by targeted therapies, stricter containment standards, increased outsourcing, and the need for specialized, compliant manufacturing.
-
Biocatalysis 101: Faster, Greener API Manufacturing
View how enzyme-driven reactions accelerate pharmaceutical ingredient manufacturing, improve selectivity, reduce waste, lower costs, and support scalable, sustainable processes under mild conditions.
-
Green Chemistry: Real-Time Analysis For Pollution Prevention
Gaining real-time visibility into chemical processes helps stop hazardous substance formation. Process monitoring reduces waste, cuts down on reagent use, and optimizes reaction time.
-
The Principles Of Green Chemistry: Design For Degradation
Designing chemicals to degrade safely reduces environmental risk. Balancing business needs with planned degradation, starting in the early design phase, ensures a sustainable lifecycle for new molecules.
-
The Principles Of Green Chemistry: Reduce Derivatives
Design synthetic routes to minimize or eliminate unnecessary temporary blocking groups. This reduces reagent use, yield loss, and waste generation, improving overall process efficiency.
-
The Principles Of Green Chemistry: Use Of Renewable Feedstocks
Adopting renewable feedstocks is crucial for green chemistry. Innovations using bio-renewable materials can drastically reduce waste, solvent use, and process steps, leading to major benefits.
-
A Review Of The Twelve Principles Of Green Chemistry
Prevention and design are foundational to green chemistry, requiring foresight to minimize hazards from the start. Reducing reliance on solvents is a critical step toward sustainability.
-
The Principles Of Green Chemistry: Safer Solvents And Auxiliaries
Solvents account for the majority of the environmental impact in chemical synthesis. Consider adopting safer alternatives and implementing reuse strategies to reduce waste, emissions, and toxicity.
-
High Potency Active Pharmaceutical Ingredients
Safely manufacturing HPAPIs and cytotoxic compounds requires specialized expertise and purpose-built facilities. Discover solutions from process development to commercial scale, including for ADC payloads.